Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
WeLRwGrRprmeD4wU